BioCentury
ARTICLE | Company News

Novo Nordisk sales and marketing update

March 11, 2013 7:00 AM UTC

Novo Nordisk launched Tresiba insulin degludec in Denmark and the U.K. to treat Type I and II diabetes in adults. The company said the cost per five-pack of 100 unit/mL Tresiba in a 3 mL solution administered with FlexTouch pens is £72 ($108.30) in the U.K. and DKK914 ($159.40) in Denmark. The cost per three-pack of 200 unit/mL Tresiba in a 3 mL solution is £86.40 ($129.96) in the U.K. and DKK1,092 ($190.44) in Denmark. Last month, Novo Nordisk said it received a complete response letter from FDA for NDAs for Tresiba and Ryzodeg insulin degludec/insulin aspart in the indications. ...